Metal Nanoparticles-Based Delivery System Development
Metal nanoparticles (MNPs) have emerged as promising platforms for drug delivery due to their unique properties and versatile surface chemistry. At Alfa Cytology, we have established a integrated platform to help you develop novel MNPs drug delivery system (DDS) for bladder cancer.
Introduction to MNPs-Based DDS
Bladder cancer is one of the most common malignant tumors of the urinary system, with significant morbidity and mortality rates. Traditional treatment modalities, such as surgery and systemic chemotherapy, often face challenges in terms of drug penetration, limited selectivity, and adverse side effects. MNPs-based DDS have emerged as a promising strategy to address these limitations and improve the therapeutic outcomes for bladder cancer.
Fig 1. Metal-based nanoparticles in drug delivery. (Sharma A. R. et al. 2022)
MNPs, including gold nanoparticles and magnetic iron oxide nanoparticles, possess unique physicochemical properties that make them ideal candidates for drug delivery applications. Their small size, large surface area-to-volume ratio, and tunable surface chemistry provide opportunities for targeted drug delivery, controlled release, and enhanced drug stability.
Our Services
At Alfa Cytology, we offer comprehensive services in the development of MNPs-based DDS for bladder cancer. Our expertise in nanotechnology and drug delivery enables us to provide tailored solutions to meet the specific needs of bladder cancer therapy. Our services include but are not limited to:
Gold Nanoparticle Drug Delivery System Development
Alfa Cytology offers comprehensive services in the development of Gold Nanoparticle-based DDS for bladder cancer.
- Customized gold nanoparticle-liposome systems;
- Customization of gold nanoparticle-micellar systems
- Customization of gold nanoparticle-nanosphere system
- Customization of gold nanoparticle-drug conjugates
Magnetic Iron Oxide Nanoparticles Drug Delivery System Development
Our scientific team will develop a suitable solution based on the drug molecules provided by the customer, combined with the groups on the surface of magnetic iron oxide nanoparticles.
Two options are available for magnetic iron oxide nanoparticles-drug conjugates.
- Based on non-covalent bonding;
- Based on covalent bonding.
MNPs-Based DDS Advantages as a Drug Carrier
Gold Nanoparticle
- Non-toxic;
- Controllable particle size (1 to 150 nm);
- Binds to insoluble drugs to increase their solubility;
- The surface can be easily modified;
- Tracking the drug in the cell by cellular imaging.
Magnetic Iron Oxide Nanoparticles
- Biocompatibility;
- Controllable particle size (1 to 200 nm);
- Serve as imaging agents;
- Ability to couple a sufficient number of effector molecules.
Contact Us
MNPs-based DDS hold tremendous potential in the field of bladder cancer therapy. Their unique properties, including tunable surface chemistry, targeted drug delivery, and controlled release capabilities, make them attractive candidates for improving the efficacy and safety of therapeutic agents. Ongoing research is focused on further optimizing these systems, exploring new surface modifications, and investigating their applications in various disease models. Alfa Cytology is committed to advancing the development of metal nanoparticles-based drug delivery systems. If you need anything, contact us today.
Reference
- Sharma A. R., Lee Y. H., and et al. Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications. J Nanobiotechnol. 2022, 20, 501.
For research use only. Not intended for any clinical use.
Related Services
